Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRWI71
|
|||
| Drug Name |
BI 706321
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Company |
Boehringer Ingelheim Ridgefield, CT
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04978493) A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.